How Adequate is the Adequate Kidney Function for Clinical Trial Enrollment of Novel Anticancer Drugs? | ||||
| Research in Oncology | ||||
| Article 1, Volume 16, Issue 2, December 2020, Page 31-34 PDF (68.84 K) | ||||
| Document Type: Mini Review | ||||
| DOI: 10.21608/resoncol.2020.33223.1100 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Nehal Gamal1; Kyrillus S. Shohdy   2
| ||||
| 1Medical Student, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt | ||||
| 2Hematology and Medical Oncology Division, Department of Medicine, Weill Cornell Medical College, New York, NY, USA | ||||
| Abstract | ||||
| Excessively restrictive eligibility criteria hinder the enrollment of cancer patients to clinical trials. Those patients are supposed to represent the range of characteristics of the overall population with particular cancer. This, in turn, affects the generalizability of results and efficiency of the drug development process in oncology. Recent guidelines from the American Society of Clinical Oncology recommend broadening the eligibility criteria for early and late phase trials. A clearly defined rationale is essential for excluding patients. They selected specific items that commonly lead to the exclusion of patients from clinical trials, namely brain metastases, the minimum age for enrollment, human immunodeficiency virus infection, prior and concurrent malignancies, and organ dysfunction. We reviewed the clinical trials of abemaciclib and tucatinib, two novel anticancer agents, to investigate the eligibility criteria used in their ongoing trials and how the cut-offs for adequate kidney functions were defined. We provided recommendations to allow for enrollment of otherwise eligible patients. | ||||
| Keywords | ||||
| Abemaciclib; Clinical trials; Eligibility criteria; Kidney function; Tucatinib | ||||
|
Statistics Article View: 647 PDF Download: 726 |
||||
